Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF., DEC. 07, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED NEW CLINICAL AND TRANSLATIONAL DATA FROM THE ONGOING CLINICAL TRIAL OF RONDECABTAGENE AUTOLEUCEL (RONDE-CEL, ALSO KNOWN AS LYL314) IN PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL), WHICH WERE PRESENTED TODAY IN TWO ORAL PRESENTATIONS AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION. AS OF THE DATA CUTOFF DATE OF SEPTEMBER 5, 2025, RONDE-CEL CONTINUED TO DEMONSTRATE ROBUST CLINICAL RESPONSES WITH A MANAGEABLE SAFETY PROFILE APPROPRIATE FOR OUTPATIENT ADMINISTRATION. A 93% OVERALL RESPONSE RATE, A 76% COMPLETE RESPONSE RATE, AND MEDIAN PROGRESSION-FREE SURVIVAL OF 18 MONTHS WERE REPORTED FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) LBCL IN THE THIRD- OR LATER-LINE (3L+) SETTING. PATIENTS EVALUATED IN THE SECOND-LINE (2L) SETTING (94% WITH DIFFICULT-TO-TREAT PRIMARY REFRACTORY DISEASE) ACHIEVED AN 83% OVERALL RESPONSE RATE AND A 61% COMPLETE RESPONSE RATE, AND 70% OF PATIENTS WITH A COMPLETE RESPONSE REMAINED IN COMPLETE RESPONSE AT 6 MONTHS OR LONGER.

LYELL IMMUNOPHARMA PRESENTS NEW CLINICAL DATA FROM ONGOING TRIAL OF RONDE-CEL SHOWING HIGH RATES OF DURABLE COMPLETE RESPONSES IN PATIENTS WITH LARGE B-CELL LYMPHOMA AT THE 67TH ASH ANNUAL MEETING AND EXPOSITION

ACQUIRED EXCLUSIVE GLOBAL RIGHTS TO LYL273, A NOVEL GCC-TARGETED CAR T-CELL PRODUCT CANDIDATE THAT HAS DEMONSTRATED A 67% OVERALL RESPONSE RATE, AN 83% DISEASE CONTROL RATE AND A MANAGEABLE SAFETY PROFILE AT THE HIGHEST DOSE LEVEL STUDIED TO DATE IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER IN AN ONGOING U.S. PHASE 1 CLINICAL TRIAL RECEIVED RMAT DESIGNATION FROM THE U.S. FDA FOR RONDE-CEL FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY LBCL RECEIVING TREATMENT IN THE SECOND-LINE (2L) SETTING ANNOUNCED THAT TWO ABSTRACTS HIGHLIGHTING NEW CLINICAL AND TRANSLATIONAL DATA FROM THE PHASE 1/2 CLINICAL TRIAL OF RONDECEL FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA HAVE BEEN ACCEPTED FOR ORAL PRESENTATION AT THE ASH 67TH ANNUAL MEETING AND EXPOSITION IN DECEMBER ANNOUNCED THE INITIATION OF PINACLE - H2H, A PHASE 3 HEAD-TO-HEAD CAR T-CELL THERAPY CLINICAL TRIAL IN AGGRESSIVE LARGE B-CELL LYMPHOMA IN THE 2L SETTING FORMED A PINACLE  H2H STEERING COMMITTEE COMPRISED OF A DISTINGUISHED GROUP OF LYMPHOMA AND CELL THERAPY EXPERTS CASH OF APPROXIMATELY $320MILLION AT THE END OF THE THIRD QUARTER OF 2025; CURRENT CASH IS EXPECTED TO SUPPORT ADVANCING PIPELINE INTO 2027 THROUGH KEY CLINICAL MILESTONES SOUTH SAN FRANCISCO, CALIF., NOV. 12, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

LYELL IMMUNOPHARMA REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE THIRD QUARTER 2025

LYL273 HAS DEMONSTRATED A 67% OVERALL RESPONSE RATE, AN 83% DISEASE CONTROL RATE, AND A MANAGEABLE SAFETY PROFILE AT THE HIGHEST DOSE LEVEL STUDIED TO DATE IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER ENROLLED IN AN ONGOING U.S. PHASE 1 CLINICAL TRIAL LYL273 IS A GCC-TARGETED CAR T-CELL PRODUCT CANDIDATE ARMED WITH ENHANCEMENTS DESIGNED TO IMPROVE CAR T-CELL EXPANSION AND CANCER CELL KILLING LYELL MANAGEMENT WILL HOST AN INVESTOR WEBCAST AT 8:30 AM ET TODAY SOUTH SAN FRANCISCO, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED IT HAS STRENGTHENED ITS SOLID TUMOR PIPELINE BY ACQUIRING GLOBAL RIGHTS TO LYL273 (FORMERLY GCC19CART), A NOVEL AUTOLOGOUS GUANYLYL CYCLASE-C (GCC)-TARGETED CAR T-CELL PRODUCT CANDIDATE FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) AND OTHER GCC-EXPRESSING CANCERS, FROM INNOVATIVE CELLULAR THERAPEUTICS (ICT).

LYELL IMMUNOPHARMA ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO A NEXT-GENERATION CAR T-CELL PRODUCT CANDIDATE IN CLINICAL DEVELOPMENT FOR METASTATIC COLORECTAL CANCER

SOUTH SAN FRANCISCO, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING A PIPELINE OF NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT TWO ABSTRACTS HIGHLIGHTING NEW CLINICAL AND TRANSLATIONAL DATA FROM THE PHASE 1/2 CLINICAL TRIAL OF RONDECABTAGENE AUTOLEUCEL (RONDE-CEL, ALSO KNOWN AS LYL314) FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA (LBCL) WILL BE PRESENTED AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION.

LYELL ANNOUNCES TWO ORAL PRESENTATIONS FROM THE PHASE 1/2 CLINICAL TRIAL OF RONDE-CEL FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA AT THE 67TH ASH ANNUAL MEETING AND EXPOSITION

PINACLE - H2H WILL EVALUATE RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) VERSUS INVESTIGATOR'S CHOICE OF APPROVED CD19 CAR T-CELL THERAPIES IN PATIENTS WITH AGGRESSIVE LARGE B-CELL LYMPHOMA RECEIVING TREATMENT IN THE SECOND LINE (2L) SETTING RONDE-CEL IS LYELL'S NEXT-GENERATION, DUAL-TARGETING CD19/CD20 CAR T-CELL THERAPY DESIGNED TO DELIVER IMPROVED COMPLETE RESPONSE RATES AND LONGER DURATION OF RESPONSES OVER CURRENTLY APPROVED CD19 CAR T-CELL THERAPIES STEERING COMMITTEE OF DISTINGUISHED LYMPHOMA EXPERTS ESTABLISHED TO ADVISE ON THE DESIGN AND CONDUCT OF THIS FIRST-OF-ITS-KIND CAR T-CELL CLINICAL TRIAL SOUTH SAN FRANCISCO, CALIF., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THE INITIATION OF PINACLE - H2H, A PHASE 3 HEAD-TO-HEAD CAR T-CELL THERAPY RANDOMIZED CONTROLLED TRIAL AND THE FORMATION OF A STEERING COMMITTEE OF PREEMINENT LYMPHOMA EXPERTS.

LYELL IMMUNOPHARMA ANNOUNCES THE INITIATION OF A PHASE 3 HEAD-TO-HEAD CAR T-CELL THERAPY CLINICAL TRIAL IN AGGRESSIVE LARGE B-CELL LYMPHOMA AND FORMATION OF EXPERT STEERING COMMITTEE

SOUTH SAN FRANCISCO, CALIF., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, ANNOUNCED TODAY THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PRESENT AND PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE ON MONDAY, SEPTEMBER 8THAT 9:15 AM EASTERN TIME H.C.

LYELL IMMUNOPHARMA ANNOUNCES PARTICIPATION IN SEPTEMBER INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A LATE-STAGE CLINICAL COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE SECOND QUARTER ENDED JUNE30, 2025. LYELL'S LEAD CLINICAL PROGRAM, LYL314, IS A NEXT-GENERATION AUTOLOGOUS DUAL-TARGETING CD19/CD20 CAR T-CELL PRODUCT CANDIDATE UNDER EVALUATION IN PINACLE, A SINGLE-ARM PIVOTAL TRIAL ENROLLING PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN THE 3L+ SETTING AND IN A PHASE 1/2 STUDY IN THE 2L SETTING.

LYELL IMMUNOPHARMA REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE SECOND QUARTER 2025

SOUTH SAN FRANCISCO, CALIF., JULY 25, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR A PRIVATE PLACEMENT WITH CERTAIN INSTITUTIONAL AND OTHER ACCREDITED INVESTORS, FOR GROSS PROCEEDS OF UP TO APPROXIMATELY $100 MILLION.

LYELL IMMUNOPHARMA ANNOUNCES UP TO $100 MILLION EQUITY PRIVATE PLACEMENT

SOUTH SAN FRANCISCO, CALIF., JUNE 23, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, ANNOUNCED TODAY THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PARTICIPATE IN THE H.C. WAINWRIGHT HCW@HOME SERIES TAKING PLACE VIRTUALLY ON WEDNESDAY, JUNE 25, 2025, AT 12:00 PM ET.

LYELL IMMUNOPHARMA TO PARTICIPATE IN THE H.C. WAINWRIGHT HCW@HOME SERIES

SOUTH SAN FRANCISCO, CALIF., JUNE 17, 2025 (GLOBE NEWSWIRE) -- LYELL IMMUNOPHARMA, INC. (NASDAQ: LYEL), A CLINICAL-STAGE COMPANY ADVANCING NEXT-GENERATION CAR T-CELL THERAPIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED POSITIVE NEW CLINICAL DATA FROM THE MULTI-CENTER PHASE 1/2 TRIAL OF LYL314, INCLUDING DATA FROM PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL) TREATED IN THE THIRD- OR LATER-LINE (3L+) SETTING. LYL314 IS AN AUTOLOGOUS DUAL-TARGETING CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL PRODUCT CANDIDATE WITH REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) AND FAST TRACK DESIGNATIONS FROM THE FDA THAT IS IN DEVELOPMENT FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) LBCL. IN PATIENTS TREATED IN THE 3L+ SETTING (N = 25), LYL314 CONTINUED TO DEMONSTRATE ROBUST CLINICAL RESPONSES, WITH AN 88% OVERALL RESPONSE RATE AND A 72% COMPLETE RESPONSE RATE. OF THE 3L+ PATIENTS WHO ACHIEVED A COMPLETE RESPONSE, 71% REMAINED IN COMPLETE RESPONSE AT  6 MONTHS. THE SINGLE-ARM PIVOTAL PINACLE TRIAL, A SEAMLESS EXPANSION OF THE PHASE 1/2 TRIAL OF PATIENTS WITH R/R LBCL BEING TREATED IN THE 3L+ SETTING, IS UNDERWAY.

LYELL IMMUNOPHARMA ANNOUNCES POSITIVE NEW CLINICAL DATA DEMONSTRATING HIGH RATES OF DURABLE COMPLETE RESPONSES FROM THE PHASE 1/2 TRIAL OF LYL314 FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA

Lyell Immunopharma, Inc.

LYEL

Price

Financial Reports

No items found.

Press Releases

Lyell Immunopharma, Inc.

LYEL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LYEL